Simone M. Goldinger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Simone M. Goldinger has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
Reinhard Dummer
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
7 shared publications- Phil Fang Cheng
Department of Dermatology, University of Zurich Hospital and Faculty of Medicine, University of Zurich, Zurich, Switzerland
3 shared publications - Reinhard Dummer
Department of Dermatology, University Hospital Zürich, University of Zurich, 8091 Zurich, Switzerland
3 shared publications Axel Hauschild
Department of Dermatology, University Hospital Schleswig-Holstein Campus Kiel, Kiel, Germany
2 shared publications- Axel Hauschild
Schleswig-Holstein University Hospital, Kiel, Germany
2 shared publications Christoph Hoeller
Department of Dermatology, Medical University of Vienna, Vienna, Austria
2 shared publications
Latest Publications
- Open Access
- 29 March 2023
- Published by Springer Nature in Current Oncology Reports
- Vol. 25 (6) , 609-621
Chemotherapy in Cutaneous Melanoma: Is There Still a Role?
Purpose of Review: In the preceding decade, the management of metastatic cutaneous melanoma has been revolutionised with the development of highly effective therapies including immune checkpoint inhibitors (specifically CTLA-4 and PD-1 inhibitors) and targeted therapies (BRAF and MEK inhibitors). The role of chemotherapy in the contemporary management of melanoma is undefined. Recent Findings: Extended analyses highlight substantially improved 5-year survival rates of approximately 50% in patients with metastatic melanoma treated with first-line therapies. However, most patients will progress on these first-line treatments. Sequencing of chemotherapy following failure of targeted and immunotherapies is associated with low objective response rates and short progression-free survival, and thus, meaningful benefits to patients are minimal. Summary: Chemotherapy has limited utility in the contemporary management of cutaneous melanoma (with a few exceptions, discussed herein) and should not be the standard treatment sequence following failure of first-line therapies. Instead, enrolment onto clinical trials should be standard-of-care in these patients.
- 29 March 2023
- Published by Springer Nature in Current Oncology Reports
- Vol. 25 (6) , 609-621
Open AccessChemotherapy in Cutaneous Melanoma: Is There Still a Role?
Purpose of Review: In the preceding decade, the management of metastatic cutaneous melanoma has been revolutionised with the development of highly effective therapies including immune checkpoint inhibitors (specifically CTLA-4 and PD-1 inhibitors) and targeted therapies (BRAF and MEK inhibitors). The role of chemotherapy in the contemporary management of melanoma is undefined. Recent Findings: Extended analyses highlight substantially improved 5-year survival rates of approximately 50% in patients with metastatic melanoma treated with first-line therapies. However, most patients will progress on these first-line treatments. Sequencing of chemotherapy following failure of targeted and immunotherapies is associated with low objective response rates and short progression-free survival, and thus, meaningful benefits to patients are minimal. Summary: Chemotherapy has limited utility in the contemporary management of cutaneous melanoma (with a few exceptions, discussed herein) and should not be the standard treatment sequence following failure of first-line therapies. Instead, enrolment onto clinical trials should be standard-of-care in these patients.
- 1 February 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 162, 22-33
Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis
- 1 February 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 162, 22-33
Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis
- 24 September 2018
- Published by Springer Nature in Current Oncology Reports
- Vol. 20 (11) , 87
The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe
As cancer remains an increasing problem in industrial countries, the incidence of melanoma has risen rapidly in many populations during the last decades and still continues to rise. Current strategies aiming to control the disease have largely focused on improving the understanding of the interplay of causal factors for this cancer.
- 24 September 2018
- Published by Springer Nature in Current Oncology Reports
- Vol. 20 (11) , 87
The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe
As cancer remains an increasing problem in industrial countries, the incidence of melanoma has risen rapidly in many populations during the last decades and still continues to rise. Current strategies aiming to control the disease have largely focused on improving the understanding of the interplay of causal factors for this cancer.
- 1 August 2017
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 27 (4) , 400-401
Interstitial granulomatous dermatitis during talimogen laherparepvec treatment
- 1 August 2017
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 27 (4) , 400-401
Interstitial granulomatous dermatitis during talimogen laherparepvec treatment
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , 9512
Re-challenge with BRAF-directed treatment: A multi-institutional retrospective study.
9512 Background: Most patients treated with BRAF inhibitors (BRAFi) +/- MEK inhibitors (MEKi) eventually progress on treatment. Along with genetic acquired resistance, epigenetic mechanisms that could be reversed after BRAFi discontinuation have been described. The purpose of this study was to analyse outcomes for patients (pts) retreated with BRAF-directed therapy. Methods: 116 pts who received BRAFi based therapy and, after a break, were re-challenged with BRAFi +/- MEKi treated at 14 centres in Europe, US, and Australia were analysed for progression free survival (PFS) and response rate (RR), as well as factors predicting overall survival (OS) (demographics, disease stage, treatment, LDH level, duration of first BRAFi treatment, reason for first BRAFi discontinuation and interval between BRAFi stop and re-challenge). Multivariate Cox regression, regression trees and Kaplan Meier method were used. Results: Median duration of 1st BRAFi +/- MEKi treatment was 9.4 months (mts) and 7.7 mts for the subsequent treatment after discontinuation (immunotherapy 72%, other 17 %, drug holiday 11%). Brain metastases were present in 51 pts (44%). RR to re-challenge with BRAFi +/- MEKi was 43%: complete response (CR) 3%, partial response (PR) 39%, stable disease 24% and progressive disease (PD) 30%, 4% missing. Of 80 pts who previously discontinued BRAFi for PD, 31 (39%) responded (30 PR and 1 CR). Median OS from retreatment was 9.8 mts. Independent prognostic factors for survival at re-challenge included number of metastatic sites (HR = 1.32 for each additional organ with metastases, p < .001), LDH (HR = 1.37 for each multiple of the upper normal limit, p < .001), while combination of BRAFi+MEKi conferred a better prognosis vs BRAFi alone (HR = 0.5, p = .006). Pts with < 3 metastatic sites treated with BRAFi and MEKi had a better survival (median OS not reached) and pts with ≥ 3 metastatic sites and raised LDH treated with BRAFi alone had the worse outcome (median OS 4 mts). Number of metastatic sites (HR = 1.44, p < .001) and combination of BRAFi and MEKi (HR = 0.45, p < .001) were independent prognostic factors for PFS (median 5.0 mts). Conclusions: Re-challenge with BRAFi +/- MEKi induces a clinically significant response and should be considered for selected cases.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , 9512
Re-challenge with BRAF-directed treatment: A multi-institutional retrospective study.
9512 Background: Most patients treated with BRAF inhibitors (BRAFi) +/- MEK inhibitors (MEKi) eventually progress on treatment. Along with genetic acquired resistance, epigenetic mechanisms that could be reversed after BRAFi discontinuation have been described. The purpose of this study was to analyse outcomes for patients (pts) retreated with BRAF-directed therapy. Methods: 116 pts who received BRAFi based therapy and, after a break, were re-challenged with BRAFi +/- MEKi treated at 14 centres in Europe, US, and Australia were analysed for progression free survival (PFS) and response rate (RR), as well as factors predicting overall survival (OS) (demographics, disease stage, treatment, LDH level, duration of first BRAFi treatment, reason for first BRAFi discontinuation and interval between BRAFi stop and re-challenge). Multivariate Cox regression, regression trees and Kaplan Meier method were used. Results: Median duration of 1st BRAFi +/- MEKi treatment was 9.4 months (mts) and 7.7 mts for the subsequent treatment after discontinuation (immunotherapy 72%, other 17 %, drug holiday 11%). Brain metastases were present in 51 pts (44%). RR to re-challenge with BRAFi +/- MEKi was 43%: complete response (CR) 3%, partial response (PR) 39%, stable disease 24% and progressive disease (PD) 30%, 4% missing. Of 80 pts who previously discontinued BRAFi for PD, 31 (39%) responded (30 PR and 1 CR). Median OS from retreatment was 9.8 mts. Independent prognostic factors for survival at re-challenge included number of metastatic sites (HR = 1.32 for each additional organ with metastases, p < .001), LDH (HR = 1.37 for each multiple of the upper normal limit, p < .001), while combination of BRAFi+MEKi conferred a better prognosis vs BRAFi alone (HR = 0.5, p = .006). Pts with < 3 metastatic sites treated with BRAFi and MEKi had a better survival (median OS not reached) and pts with ≥ 3 metastatic sites and raised LDH treated with BRAFi alone had the worse outcome (median OS 4 mts). Number of metastatic sites (HR = 1.44, p < .001) and combination of BRAFi and MEKi (HR = 0.45, p < .001) were independent prognostic factors for PFS (median 5.0 mts). Conclusions: Re-challenge with BRAFi +/- MEKi induces a clinically significant response and should be considered for selected cases.
- 12 April 2017
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 31 (10) , 1638-1640
Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600‐mutated melanoma
Background: The combination treatment with BRAF and MEK inhibitors is amongst the current standard of care for stage IIIC/IV BRAF‐mutated melanoma. However, therapeutic options are limited once patients have progressed upon both targeted and immunotherapy.Objective: To investigate whether retreatment with BRAF and MEK inhibitor combination is an option for patients with metastatic BRAF‐mutated melanoma upon previous progression on kinase inhibitors.Methods: Two patients with metastatic BRAF‐mutated melanoma were rechallenged with BRAF and MEK inhibitor combination after progression on targeted therapy and subsequent immunotherapy with anti‐CTLA‐4 and anti‐PD‐1 antibodies.Results: Both patients responded to retreatment. Responses were limited to a few months and associated with a considerable increase in quality of life.Conclusion: Retreatment with BRAF and MEK inhibitors may present a feasible treatment option upon progression on both kinase inhibitors and immunotherapy, and should be considered when all other treatment options have been exhausted.
- 12 April 2017
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 31 (10) , 1638-1640
Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600‐mutated melanoma
Background: The combination treatment with BRAF and MEK inhibitors is amongst the current standard of care for stage IIIC/IV BRAF‐mutated melanoma. However, therapeutic options are limited once patients have progressed upon both targeted and immunotherapy.Objective: To investigate whether retreatment with BRAF and MEK inhibitor combination is an option for patients with metastatic BRAF‐mutated melanoma upon previous progression on kinase inhibitors.Methods: Two patients with metastatic BRAF‐mutated melanoma were rechallenged with BRAF and MEK inhibitor combination after progression on targeted therapy and subsequent immunotherapy with anti‐CTLA‐4 and anti‐PD‐1 antibodies.Results: Both patients responded to retreatment. Responses were limited to a few months and associated with a considerable increase in quality of life.Conclusion: Retreatment with BRAF and MEK inhibitors may present a feasible treatment option upon progression on both kinase inhibitors and immunotherapy, and should be considered when all other treatment options have been exhausted.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 3026
The peripheral blood TCR repertoire to facilitate patient stratification for immune checkpoint blockade inhibition in metastatic melanoma.
3026 Background: Anti-PD-1 and/or anti-CTLA-4 antibodies show durable responses in metastatic melanoma. Measuring the diversity of T lymphocytes in pre-treatment liquid biopsies may help stratify patients for immunotherapy. Methods: In this retrospective blinded study, we used a multi-N-plex polymerase chain reaction (PCR) assay to measure TCR combinatorial diversity from genomic DNA in peripheral blood from melanoma patients treated with anti-CTLA-4 (n = 40) or anti-PD-1 (n = 36). A receiver operating characteristic (ROC) curve was used to determine the threshold for dichotomized analysis (i.e. low vs. high diversity) according to RECIST 1.1. Association with benefit in the low vs. high groups was assessed through a Fisher’s exact test. OS, PFS, and ORR were tested with ALC, ANC, LDH, S100 levels, and TCR diversity (DS) in a univariate model. Significant (p < 0.10) candidate prognostic factors from the univariate analysis were included in a multivariate Cox regression to define the added value of each variable on ORR, OS and PFS prediction. Results: A diversity score (DS) < 20% was associated with progressive or stable disease (p = 0.016) in anti-CTLA-4 treated patients. In contrast, a DS < 20% was associated with partial or complete response in 5 of the 12 responders (p = 0.0021) receiving anti-PD-1, and all non-responders (24) had a high DS > 20%. All low DS patients were non-responders in the anti-CTLA-4 cohort (100% negative predictive value), and were all responders in the anti-PD1 cohort (100% positive predictive value). In multivariate analysis with ALC, ANC, LDH, and age, a DS < 20% was an independent predictive marker of response to anti-PD-1 (p = 0.0001), with ALC > 1.4 (p = 0.027) and ANC > 4.8G/L (p = 0.016). A DS < 20% was found to be an independent prognostic marker of PFS (p = 0.040) with ANC > 4.8G/L (p = 0.0071). Conclusions: Patients with low DS did not benefit from anti-CTLA-4. In contrast, low DS patients receiving anti-PD-1 benefitted from the therapy. Thus, the TCR repertoire is a predictive biomarker of response that might help physicians choose best immune checkpoint modulators. Several studies are ongoing to validate these results.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 3026
The peripheral blood TCR repertoire to facilitate patient stratification for immune checkpoint blockade inhibition in metastatic melanoma.
3026 Background: Anti-PD-1 and/or anti-CTLA-4 antibodies show durable responses in metastatic melanoma. Measuring the diversity of T lymphocytes in pre-treatment liquid biopsies may help stratify patients for immunotherapy. Methods: In this retrospective blinded study, we used a multi-N-plex polymerase chain reaction (PCR) assay to measure TCR combinatorial diversity from genomic DNA in peripheral blood from melanoma patients treated with anti-CTLA-4 (n = 40) or anti-PD-1 (n = 36). A receiver operating characteristic (ROC) curve was used to determine the threshold for dichotomized analysis (i.e. low vs. high diversity) according to RECIST 1.1. Association with benefit in the low vs. high groups was assessed through a Fisher’s exact test. OS, PFS, and ORR were tested with ALC, ANC, LDH, S100 levels, and TCR diversity (DS) in a univariate model. Significant (p < 0.10) candidate prognostic factors from the univariate analysis were included in a multivariate Cox regression to define the added value of each variable on ORR, OS and PFS prediction. Results: A diversity score (DS) < 20% was associated with progressive or stable disease (p = 0.016) in anti-CTLA-4 treated patients. In contrast, a DS < 20% was associated with partial or complete response in 5 of the 12 responders (p = 0.0021) receiving anti-PD-1, and all non-responders (24) had a high DS > 20%. All low DS patients were non-responders in the anti-CTLA-4 cohort (100% negative predictive value), and were all responders in the anti-PD1 cohort (100% positive predictive value). In multivariate analysis with ALC, ANC, LDH, and age, a DS < 20% was an independent predictive marker of response to anti-PD-1 (p = 0.0001), with ALC > 1.4 (p = 0.027) and ANC > 4.8G/L (p = 0.016). A DS < 20% was found to be an independent prognostic marker of PFS (p = 0.040) with ANC > 4.8G/L (p = 0.0071). Conclusions: Patients with low DS did not benefit from anti-CTLA-4. In contrast, low DS patients receiving anti-PD-1 benefitted from the therapy. Thus, the TCR repertoire is a predictive biomarker of response that might help physicians choose best immune checkpoint modulators. Several studies are ongoing to validate these results.
- Open Access
- 13 December 2015
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 174 (4) , 823-830
Prognostic relevance of lactate dehydrogenase and serum S100 levels in stage IV melanoma with knownBRAFmutation status
Background Activating mutations of BRAF provide an important treatment target in patients with melanoma. The prognostic role of several biochemical markers in relation to mutation status is not clear. Objectives To analyse the prognostic significance of BRAF mutation in patients with melanoma and correlate it to different markers. Methods In total, 162 patients with stage IV melanoma and known BRAF mutation status were included. Clinical, histopathological and laboratory information was collected and compared between patients with BRAF mutant (BRAFm) and wild‐type (BRAFwt) melanoma at the time of first distant metastasis. Results In total, 88 patients (54%) had BRAFm melanoma (V600E/V600K). At the first distant metastasis, S100B levels in BRAFm patients were more frequently elevated (P = 0·01) and significantly higher (P = 0·02). Median overall survival (mOS) was significantly longer in BRAFwt patients with normal compared with patients with elevated S100B levels (P < 0·01). In BRAFm melanoma, elevated S100B levels showed no prognostic influence (P = 0·18). Elevated lactate dehydrogenase (LDH) levels had a significantly negative impact on mOS in both groups. mOS was increased for BRAFm patients treated with a BRAF inhibitor (BRAFi) compared with BRAFm patients not receiving BRAFi (P = 0·01). No difference in mOS between BRAFm patients who did not receive BRAFi treatment and BRAFwt patients was observed. Conclusions Better mOS was observed in BRAFm patients treated with BRAFi. BRAFm patients not treated with BRAFi show similar survival curves to BRAFwt patients. Elevated LDH is a BRAF‐independent prognostic parameter; S100B has prognostic significance in BRAFwt melanoma only.
- 13 December 2015
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 174 (4) , 823-830
Open AccessPrognostic relevance of lactate dehydrogenase and serum S100 levels in stage IV melanoma with knownBRAFmutation status
Background Activating mutations of BRAF provide an important treatment target in patients with melanoma. The prognostic role of several biochemical markers in relation to mutation status is not clear. Objectives To analyse the prognostic significance of BRAF mutation in patients with melanoma and correlate it to different markers. Methods In total, 162 patients with stage IV melanoma and known BRAF mutation status were included. Clinical, histopathological and laboratory information was collected and compared between patients with BRAF mutant (BRAFm) and wild‐type (BRAFwt) melanoma at the time of first distant metastasis. Results In total, 88 patients (54%) had BRAFm melanoma (V600E/V600K). At the first distant metastasis, S100B levels in BRAFm patients were more frequently elevated (P = 0·01) and significantly higher (P = 0·02). Median overall survival (mOS) was significantly longer in BRAFwt patients with normal compared with patients with elevated S100B levels (P < 0·01). In BRAFm melanoma, elevated S100B levels showed no prognostic influence (P = 0·18). Elevated lactate dehydrogenase (LDH) levels had a significantly negative impact on mOS in both groups. mOS was increased for BRAFm patients treated with a BRAF inhibitor (BRAFi) compared with BRAFm patients not receiving BRAFi (P = 0·01). No difference in mOS between BRAFm patients who did not receive BRAFi treatment and BRAFwt patients was observed. Conclusions Better mOS was observed in BRAFm patients treated with BRAFi. BRAFm patients not treated with BRAFi show similar survival curves to BRAFwt patients. Elevated LDH is a BRAF‐independent prognostic parameter; S100B has prognostic significance in BRAFwt melanoma only.
- Open Access
- 1 October 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (10) , e0139438
Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?
Ipilimumab and tremelimumab are human monoclonal antibodies (Abs) against cytotoxic T-lymphocyte antigen-4 (CTLA-4). Ipilimumab was the first agent to show a statistically significant benefit in overall survival in advanced melanoma patients. Currently, there is no proven association between the BRAFV600 mutation and the disease control rate in response to ipilimumab. This analysis was carried out to assess if BRAFV600 and NRAS mutation status affects the clinical outcome of anti-CTLA-4-treated melanoma patients. This is a retrospective multi-center analysis of 101 patients, with confirmed BRAF and NRAS mutation status, treated with anti-CTLA-4 antibodies from December 2006 until August 2012. The median overall survival, defined from the treatment start date with the anti-CTLA-4. Abs-treatment to death or till last follow up, of BRAFV600 or NRAS mutant patients (n = 62) was 10.12 months (95% CI 6.78–13.2) compared to 8.26 months (95% CI 6.02–19.9) in BRAFV600/NRASwt subpopulation (n = 39) (p = 0.67). The median OS of NRAS mutated patients (n = 24) was 12.1 months and although was prolonged compared to the median OS of BRAF mutated patients (n = 38, mOS = 8.03 months) or BRAFV600/NRASwt patients (n = 39, mOS = 8.26 months) the difference didn’t reach statistical significance (p = 0.56). 69 patients were able to complete 4 cycles of anti-CTLA-4 treatment. Of the 24 patients treated with selected BRAF- or MEK-inhibitors, 16 patients received anti-CTLA 4 Abs following either a BRAF or MEK inhibitor with only 8 of them being able to finish 4 cycles of treatment. Based on our results, there is no difference in the median OS in patients treated with anti-CTLA-4 Abs implying that the BRAF/NRAS mutation status alone is not sufficient to predict the outcome of patients treated with anti-CTLA-4 Abs.
- 1 October 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (10) , e0139438
Open AccessAnalysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?
Ipilimumab and tremelimumab are human monoclonal antibodies (Abs) against cytotoxic T-lymphocyte antigen-4 (CTLA-4). Ipilimumab was the first agent to show a statistically significant benefit in overall survival in advanced melanoma patients. Currently, there is no proven association between the BRAFV600 mutation and the disease control rate in response to ipilimumab. This analysis was carried out to assess if BRAFV600 and NRAS mutation status affects the clinical outcome of anti-CTLA-4-treated melanoma patients. This is a retrospective multi-center analysis of 101 patients, with confirmed BRAF and NRAS mutation status, treated with anti-CTLA-4 antibodies from December 2006 until August 2012. The median overall survival, defined from the treatment start date with the anti-CTLA-4. Abs-treatment to death or till last follow up, of BRAFV600 or NRAS mutant patients (n = 62) was 10.12 months (95% CI 6.78–13.2) compared to 8.26 months (95% CI 6.02–19.9) in BRAFV600/NRASwt subpopulation (n = 39) (p = 0.67). The median OS of NRAS mutated patients (n = 24) was 12.1 months and although was prolonged compared to the median OS of BRAF mutated patients (n = 38, mOS = 8.03 months) or BRAFV600/NRASwt patients (n = 39, mOS = 8.26 months) the difference didn’t reach statistical significance (p = 0.56). 69 patients were able to complete 4 cycles of anti-CTLA-4 treatment. Of the 24 patients treated with selected BRAF- or MEK-inhibitors, 16 patients received anti-CTLA 4 Abs following either a BRAF or MEK inhibitor with only 8 of them being able to finish 4 cycles of treatment. Based on our results, there is no difference in the median OS in patients treated with anti-CTLA-4 Abs implying that the BRAF/NRAS mutation status alone is not sufficient to predict the outcome of patients treated with anti-CTLA-4 Abs.
- 5 June 2015
- Published by Wiley in The Journal of Dermatology
- Vol. 42 (9) , 927-928
Histological evaluation of a “residual” metastasis after ipilimumab therapy in a patient with advanced melanoma
- 5 June 2015
- Published by Wiley in The Journal of Dermatology
- Vol. 42 (9) , 927-928
Histological evaluation of a “residual” metastasis after ipilimumab therapy in a patient with advanced melanoma